Drug intelligence / Profile preview

WD-1602

Development stage: Phase 1
Lead developer: Hong Kong WD Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

WD-1602 is an oral thrombin inhibitor developed as an anticoagulant. Its mechanism of action involves direct inhibition of thrombin, a key enzyme in the coagulation cascade responsible for converting fibrinogen to fibrin, thereby preventing blood clot formation. WD-1602 has been evaluated in clinical studies for its bioequivalence to Pradaxa (dabigatran etexilate), suggesting it is intended as a potential alternative or generic version of this established anticoagulant. The drug has not received FDA designation and is being developed by Hong Kong WD Pharmaceutical Co., Limited.

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on WD-1602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-1602.

Explore the full profile